Maze Therapeutics

working to translate genetic insights into effective precision medicines.

In the summer of 2018, we had an idea. A big idea, inspired by the recent dramatic advances in the field of genetics and the significant gaps in translating those into medicines. We set out to use these advances in harnessing the power of genetics to transform the lives of patients, which became our company’s mission.

Today, we are a clinical stage company developing small molecule precision medicines for common diseases with 3 clinical stage programs and several programs in drug discovery also being developed through the Maze Compass™ Platform.

Our Core Values

We live each day by our Maze values:

Further Together.

Impact Obsessed.

Stand True.

Leadership Team

Senior Management

Board of Directors

Jason Coloma, Ph.D.

Chief Executive Officer

Dr. Jason Coloma is the Chief Executive Officer of Maze Therapeutics. Prior to his appointment to CEO, he was Maze’s chief operating officer and a venture partner at Third Rock Ventures, where he was instrumental in the founding and launch…

View full bio

Herve Hoppenot

CHAIRMAN OF OUR BOARD OF DIRECTORS, CURRENT BOARD MEMBER and FORMER CEO OF INCYTE

Mr. Hoppenot joined Maze Therapeutics, Inc. as the Chairman of our board of directors in October 2025. Mr. Hoppenot currently serves on the board of directors of lncyte Corporation, where he has served since January 2014. He is also a…

View full bio

Charles Homcy, M.D.

FORMER CHAIRMAN OF THE MAZE BOARD, CHAIRMAN OF PHARMACEUTICALS AND LEAD DIRECTOR, BRIDGEBIO PHARMA

Charles Homcy, M.D., is a former partner at Third Rock Ventures. He is a co-founder of BridgeBio Pharma, Inc. and has served as a member of its board of directors since November 2018, as Chairman of Pharmaceuticals since February 2019,…

View full bio

Nancy Andrews, M.D., Ph.D

EXECUTIVE VICE PRESIDENT AND CHIEF SCIENTIFIC OFFICER, BOSTON CHILDREN’S HOSPITAL

Nancy Andrews, M.D., Ph.D., has extensive experience as a physician, scientist, professor and senior administrator at leading academic institutions and hospitals. Her distinguished career spans more than 30 years, with leadership roles at Harvard Medical School, Duke University, and Boston…

View full bio

Jonathan Lim, M.D.

Founder and managing partner, City Hill Ventures

Jonathan Lim, M.D., is the founder and managing partner at City Hill Ventures. In addition to his role at City Hill, Dr. Lim is a venture partner at ARCH Venture Partners, chairman, chief executive officer and co-founder at Erasca, and…

View full bio

Richard Scheller, Ph.D.

Former head of therapeutics and chief scientific officer, 23andMe

Dr. Richard Scheller is the former head of therapeutics and chief scientific officer of 23andMe. Prior to his role there, he spent 14 years at Genentech where he was executive vice president of research and early development. From 1982 to…

View full bio

Catherine Angell Sohn, Pharm.D.

FORMER Senior Vice President GLAXOSMITHKLINE; ADJUNCT PROFESSOR AT UCSF

Catherine Angell Sohn, Pharm.D., is an experienced biopharmaceutical executive and board member with expertise in strategy, strategic product development, business development/partnering, commercialization of new medicines and corporate governance. Dr. Sohn currently serves as an independent director on the Boards of…

View full bio

Daniel K. Spiegelman

FORMER Executive Vice President, Chief Financial Officer, BIOMARIN PHARMACEUTICALS

Daniel K. Spiegelman has served as a chief financial officer in several diversified biotechnology companies spanning 30 years. He was most recently executive vice president and chief financial officer of BioMarin Pharmaceuticals, Inc., a pharmaceutical company focused on development of…

View full bio

Neil Exter, M.B.A.

Partner, Third Rock Ventures

Neil is a partner at Third Rock Ventures. He joined TRV shortly after its inception over 17 years ago. At Third Rock, Neil has been an operating executive or member of the BOD at over fifteen portfolio companies including Constellation…

View full bio

OUR VISION IS TO BUILD THE NEXT GENERATION PRECISION MEDICINES COMPANY

Charles Homcy

M.D., CEO; Partner, Third Rock Ventures

Dr. Charles Homcy is a partner at Third Rock Ventures, where he focuses on the formation of companies that discover and develop novel therapeutic approaches. He brings significant experience building and leading successful biotech companies and has played an integral role in the launching and building of Third Rock Ventures’ portfolio companies, including Ambys Medicines, Global Blood Therapeutics, Pliant Therapeutics, Relay Therapeutics, Goldfinch Bio, CytomX and MyoKardia.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.